Do not enroll any **new** subjects after: 10/182018

Pain after total knee arthroplasty: a comparison of combined continuous adductor canal block with infiltration of local anesthetic between the popliteal artery and capsule of the knee (IPACK) block versus continuous adductor canal block alone on postoperative analgesia. IRB# 2016.307.C	
Principal Investigator: Matthew Patt	erson
Sub-Investigators: Kim Sanford Bla	nd, Clint Elliott, Kristie Osteen, Leslie
	Thomas, Jillian Vitter, Edward Weller
	Dane Yuratich, George Chimento
	bane raration, cooligo crimiento
Are you in any other research studies?	Yes No please initial your response
Ochsner study the nature of disease a treatment. This is called clinical resea	a research study. The doctors and staff at nd attempt to improve methods of diagnosis and rch. Understanding this study's risks and benefit gment about whether to be part of it. This
doctor or the study staff to explain any	that you do not understand. Please ask the study words or information that you do not clearly nsigned copy of this consent form to think about making your decision.
purpose of regular medical care is to	ot the same as getting regular medical care. The improve your health. The purpose of a research this study does not replace your regular medical
In this consent form, "you" always reference representative, please remember that	rs to the subject. If you are a legally authorized "you" refers to the study subject.
PURPOSE	
The purpose of this study is to determi	ne whether an additional nerve block targeting

posterior nerve endings improves pain control, increases function, and speeds recovery following total knee replacement compared to no additional posterior block. You have been asked to participate in this study because you are undergoing a single-sided total knee replacement.

LENGTH OF STUDY AND NUMBER OF PARTICIPANTS

 Your participation in this research study will be limited to your hospital admission for total knee arthroplasty (approximately 1-3 days). There will be one site nationwide enrolling **72** subjects for participation in this study. At Ochsner **72** subjects will be enrolled.

PROCEDURE

If you agree to be in this study, we will ask you to do the following things: You will be randomized into one of two groups. The randomization procedure to decide which group you are in is like flipping a coin. In the study group you will receive a nerve block that targets posterior nerve endings that is currently performed at Ochsner Medical Center prior to all total knee replacements. In the other group you will receive a placebo injection. This means that a small amount of sterile saline will be injected just under the skin surface and no active medication will be given. The study will involve follow-up while in the hospital and after discharge while the continuous nerve block catheters are in place (approximately 48 hours after discharge).

<u>RISKS</u>

General / Unforeseeable

Risks of participating in the study are the same as with routine care. These include mild discomfort during procedure, incomplete pain relief, unlikely bleeding and infection risks, unlikely local anesthetic spread to cause temporary foot drop or expanded nerve block, rare but potentially serious nerve injury, and rare but serious local anesthetic toxicity, and rare but serious allergy. These risks will be managed as they would with routine care through use of ultrasound imaging modalities and adhering to clean procedure techniques. Your knee pain may not improve or may get worse despite participation in this research study.

Louisiana law requires us to set forth the known risks of a medical treatment, including the risks, if any, of death, brain damage, quadriplegia (paralysis in all arms and legs), paraplegia (paralysis of both legs), the loss or loss of function of any organ or limb, and disfiguring scars, which might be associated with a necessary procedure. Any clinical study carries with it risks of which we may be unaware at this time, including those listed in this paragraph.

Reproductive Risks

The treatment or procedure may involve unforeseeable risks to the subject, or embryo or fetus, if the subject becomes pregnant. Because the possibility of injury or harmful effects to an embryo or fetus exists you must not be pregnant or conceive a child while in this clinical trial. Acceptable methods of contraception include intrauterine device, spermicide and barrier (e.g., condom, diaphragm) method, oral contraceptives (birth control pills) and total abstinence. Please discuss the best choice for you and your partner with your study doctor.

If you or your partner becomes pregnant while participating in this study, you MUST contact your study doctor immediately.

POTENTIAL BENEFITS

You may not receive direct personal or health benefit from taking part in this study. However, the information gained from your participation in this study may be used to help others in the future.

COSTS

There are no known additional costs. Your insurance bill will be unchanged from what it would be with routine care if you choose not to participate in the study. Your responsibility for your co-pay is unchanged from that if you chose routine care.

Although the Sponsor may pay for certain study-related items and services, any other tests, procedures, or medications that may be necessary for the treatment of your medical condition will be billed to your insurance in the normal way. You may be responsible for co-payments or deductibles. These costs are not covered by this research study. If you have any questions about treatment for which you may be responsible for paying, please discuss this with your physician or study staff.

PAYMENT FOR PARTICIPATION AND/OR REIMBURSEMENT OF EXPENSES

No payment, reimbursement of expenses, or compensation is provided for study participants.

ALTERNATIVE METHODS/TREATMENTS

An alternative is to not take part in the study. The option of continuing with standard clinical care at Ochsner Medical Center would include the study intervention. You do not have to join this study. If you do not join, your care at Ochsner will not be affected.

STUDY RELATED QUESTIONS AND COMPENSATION FOR INJURY

134135

If you have any questions concerning your participation in this study or if at any time you feel you have experienced a research-related injury or a reaction to a study drug, contact:

137138

140

136

Dr. Matthew Patterson at Ochsner Medical Center

Address: Dept. of Anesthesiology, 1514 Jefferson Hwy, New Orleans LA 70121

Phone: 504-842-3755

141142143

144

145

146

147

148

149

150

If you believe you are injured as a direct result of your participation in this study, you should seek appropriate medical attention and immediately contact your study doctor at the number provided above. Medical treatment and/or hospitalization, if necessary for such injuries, is available. This medical treatment and/or hospitalization is not free of charge. You, your insurance company or the Sponsor may be billed for the care you receive for the injury. We will try to get these costs paid for you, but you may be responsible for some of them. You may be responsible for all co-payments and deductibles required under your insurance. By signing this consent form you have not given up any legal rights.

151152153

QUESTIONS ABOUT YOUR RIGHTS

154155

If you have questions about your rights as a research subject, you may contact:

156157

158

Ochsner Clinic Foundation Institutional Review Board 1514 Jefferson Highway New Orleans, LA 70121

159160

Telephone: 1-504-842-3535

161162

163

164

165

The Institutional Review Board (IRB) is a group of people who perform independent review of research for human subject protection. You may contact the IRB to discuss any problems, concerns or questions you have about research. The IRB can assist you in obtaining information about research and encourages input from research subjects.

166167

VOLUNTARY PARTICIPATION AND WITHDRAWAL FROM THE RESEARCH

168169

170

171

172

Participation in this study is voluntary. You may decide not to participate in this study or you may withdraw from this study at any time without penalty or loss of benefits to which you are otherwise entitled at this site. If you leave the study before the final regularly scheduled visit, you may be asked by the study doctor to make a final visit for some end of study procedures.

173174175

You will be informed of any significant new findings that develop during the investigation that may affect your willingness to continue in the study.

176177178

You should tell your study doctor about all of your past and present health conditions

and allergies of which you are aware, and all drugs and medications which you are presently using.

181 182

Your participation in this study may be stopped at any time by the study doctor or the sponsor without your consent because:

183 184 185

• the study doctor thinks it necessary for your health or safety;

you have not followed study instructions;

- the sponsor has stopped the study; or
- administrative reasons require your withdrawal.

188 189 190

187

CONFIDENTIALITY

191 192

193

Your identity and your personal records will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available. Confidentiality will be maintained during and after your participation in this study.

194 195 196

197

198

A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required by U.S. law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

199 200

HIPAA AUTHORIZATION TO RELEASE INFORMATION FOR RESEARCH

201202203

204

205

206

207

208

Under federal law (the "Privacy Rule"), your Protected Health Information (PHI) that is created or obtained during this clinical research study cannot be "used" to conduct the research or "disclosed" (given to anyone) for research purposes without your permission. This permission is called an "Authorization". Therefore, you may not take part in this study unless you sign this Authorization. If you volunteer to take part in this research study, you have the right to know that others may know your identity. Study information may identify you in the following ways.

209210

NameAddress

211212

Telephone number

213214

Other details about you including your past medical records

215216

This study includes a number of researchers, businesses and government agencies. They may use your health information and share it with others. We want you to know who may use this information and how they may use it.

217218219

We also want to tell you about your rights concerning the use of your personal information before you agree to take part in the study.

220221222

Who may use and give out information about you?

The Investigator (study doctor) and research staff will have information about your health that tells us your identity. They may give this information to others during and after the study.

226227

228

229

230

Who may see this information?

The study sponsor also may see your health information and know your identity. "Sponsor" includes any people or companies working for or with the sponsor or owned by the sponsor. They all have the right to see information about you during and after the study.

231232233

234

235

236

237

238

239

240

241

The following people, agencies and businesses may get information from us that shows who you are.

Doctors and healthcare professionals taking part in the study

- U.S. Food and Drug Administration (FDA)
- U.S. Department of Health and Human Services (DHHS)
- Government agencies in other countries
- Government agencies that must receive reports about certain diseases
- Ochsner Clinic Foundation Research & Compliance Offices
- Ochsner Clinic Foundation Institutional Review Board (IRB)
- Third party vendors as authorized by Ochsner Clinic Foundation

242243244

245

246

What information may be used and shared?

If you decide to be in this study, medical information that identifies you and relates to your participation will be created. This may include the following types of medical information.

247248

249

250

• Information obtained from the procedures used to find out whether you are eligible to take part in this study. This may include physical examinations, blood and urine tests, x-rays and other procedures or tests, and any other information that you may release to us, including information about your health history.

251252253

254

255

256

 Information obtained in the course of the study including information about your response to any study treatments you receive, information related to study visits and phone calls, physical examinations, blood and urine tests, x-rays and other tests or procedures that may be performed, and other medical information relating to your participation in this study.

257258259

260

261

262

263

Why will this information be used and/or shared?

Information about you and your health, that might identify you, may be given to others to carry out the research study. The sponsor will analyze and evaluate the results of the study. In addition, people from the sponsor and its consultants will be visiting the research site. They will follow how the study is done, and they will be reviewing your information for this purpose.

264265266

The information may be given to the FDA. It may also be given to governmental

agencies in other countries. This is done so the sponsor can receive marketing approval for new products resulting from this research. The information may also be used to meet the reporting requirements of governmental agencies.

269270271

267

268

The results of this research may be published in scientific journals or presented at medical meetings, but your identity will not be disclosed.

272273274

The information may be reviewed by the Ochsner Institutional Review Board. The Ochsner Research & Compliance Offices may review this research in their oversight and auditing roles.

276277278

279

280

275

What if I decide not to give permission to use and give out my health information? By signing this consent form, you are giving permission to use and give out the health information listed above for the purposes described above. If you refuse to give permission, you will not be able to be in this research.

281 282 283

284

285

May I review or copy the information obtained from me or created about me?

You have the right to review and copy your health information. However, if you decide to be in this study and sign this permission form, you will not be allowed to look at or copy your information until after the research is completed.

286287288

289

May I withdraw or revoke (cancel) my permission?

Yes, but this authorization (permission) will not expire (end) until it is no longer required by the Sponsor unless you revoke (cancel) it in writing.

290291292

You may withdraw or take away your permission to use and disclose your health information at any time. You do this by sending written notice to the study doctor. If you withdraw your permission, you will not be able to continue being in this study.

294295296

297298

293

When you withdraw your permission, no new health information that might identify you will be gathered after that date. Information that has already been gathered may still be used and given to others. This would be done if it were necessary for the research to be reliable.

299300301

302

303

304

305

Is my health information protected after it has been given to others?

If you give permission to give your identifiable health information to a person or business, the information may no longer be protected. If your health information is given to the parties listed above and/or to others who are not required to comply with these federal laws your information may no longer be protected. There is a risk that your information will be released to others without your permission.

306307308

309

Your personal information may be disclosed if required by law. Your records for this study may be sent by facsimile transmission (FAX machine) or over the Internet. It is possible that your records could be sent to the wrong person.

310311

312 How long is my information kept? 313 Ochsner Clinic Foundation policy requires that all files related to a research study are 314 stored for ten (10) years after the research study has been closed at the Ochsner site. 315 316 Do not sign this consent form unless you have had a chance to ask questions 317 and have received satisfactory answers to all of your questions. 318 319 If you agree to participate in this study, you will receive a signed and dated copy 320 321 of this consent form for your records. 322 323 CONSENT 324 I have been informed about this study's purpose, procedures, possible benefits and 325 risks, and the use and disclosure of my health care information from this research. All my 326 questions about the study and my participation in it have been answered. I freely 327 consent to participate in this research study. I authorize the use and disclosure of my 328 health information to the parties listed in the authorization section of this consent for the 329 purposes described above. By signing this consent form I have not waived any of the 330 legal rights that I otherwise would have as a subject in a research study. 331 332 333 334 **CONSENT SIGNATURE** 335 336 337 338 **Patient Signature Printed Name** 339 Date 340 341 342 Signature of Legally Authorized Representative Printed Name Date 343 (when applicable) 344 345 346 347 Authority of Subject's Legally Authorized Representative or Relationship to Subject 348 349 350 351 Person Obtaining Consent - Signature **Printed Name** 352 Date 353 354 355

356

357	
358	Use the following only if applicable
359	
360	
361	IMPARTIAL WITNESS STATEMENT (IF APPLICABLE)
362	
363	If this consent and authorization document is read to the subject because the subject is
364	unable to read the document, an impartial witness (a person, who is independent of the
365	trial, who cannot be unfairly influenced by people involved with the trial, who attends the
366	informed consent process if the subject cannot read, and who reads the informed
367	consent and any other written information supplied to the subject) must be present for
368	the consent and sign the following statement:
369	Lattest that the information in this consent and outherization was evaluized to and
370	I attest that the information in this consent and authorization was explained to, and
371	understood by the subject. I also attest that the subject agreed to participate in this
372	research study.
373374	
375	
376	Printed Name of Impartial Witness
377	Trinted Name of impartial Withess
378	
379	
380	
381	Signature of Impartial Witness Date
382	
383	
384	Note: This signature block cannot be used for translations into another language. A
385	translated consent form, with the translation approved by the IRB, is necessary for
386	enrolling subjects who do not speak English.